GENFIT Triggers $20M Milestone as Ipsen’s Iqirvo® Hits $208M in First Year
Event summary
- Ipsen’s Iqirvo® achieved $208M in net sales in 2025, triggering a $20M milestone payment to GENFIT ahead of schedule.
- Ipsen confirmed plans to initiate a Phase 3 trial for Iqirvo® in primary sclerosing cholangitis (PSC), a new indication.
- GENFIT’s Phase 1b study for cholangiocarcinoma (CCA) is progressing with no dose-limiting toxicities reported.
- GENFIT received an additional €30M tranche under its royalty-financing agreement with HCRx.
The big picture
GENFIT’s financial position is strengthened by Ipsen’s commercial success with Iqirvo®, which exceeded expectations in its first year. The initiation of a Phase 3 trial for PSC opens a new market opportunity, while GENFIT’s ongoing clinical programs in oncology and liver diseases position it for potential long-term growth. The company’s ability to secure non-dilutive financing further enhances its strategic flexibility in a competitive biopharmaceutical landscape.
What we're watching
- Commercial Trajectory
- Whether Ipsen can sustain Iqirvo®’s rapid revenue growth in PBC and expand into PSC.
- Clinical Development
- The pace at which GENFIT advances its GNS561 program and Phase 2 data readouts.
- Financial Flexibility
- How GENFIT leverages the $20M milestone and €30M tranche to fund future R&D and strategic initiatives.
Related topics